Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: A systematic review

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Visser, Benjamin J ^a,b,c   Wieten, Rosanne W ^a   Kroon, Daniëlle ^a,b   Nagel, Ingeborg M ^a   Bélard, Sabine ^a,d   Van Vugt, Michèle ^a   Grobusch, Martin P ^a,b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Gabon)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ACT; Artemisinin combination therapy; Non falciparum malaria; Plasmodium knowlesi; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax

Indexed keywords

ARTEMISININ; ARTESUNATE; CHLOROQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; EVIDENCE BASED MEDICINE; FEVER; HUMAN; MALARIA; META ANALYSIS; OUTCOME ASSESSMENT; PARASITEMIA; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM MALARIAE INFECTION; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH PRIORITY; REVIEW; SYSTEMATIC REVIEW; ADVERSE EFFECTS; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MALARIA; TREATMENT OUTCOME;

EID: 84964313032     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-463     Document Type: Review

References (117)

1. Jelinek T, Schulte C, Behrens R, Grobusch MP, Coulaud JP, Bisoffi Z, Matteelli A, Clerinx J, Corachan M, Puente S, Gjørup I, Harms G, Kollaritsch H, Kotlowski A, Björkmann A, Delmont JP, Knobloch J, Nielsen LN, Cuadros J, Hatz C, Beran J, Schmid ML, Schulze M, Lopez-Velez R, Fleischer K, Kapaun A, McWhinney P, Kern P, Atougia J, Fry G, et al: Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis 2002, 34:572-576.
2. Gautret P, Schlagenhauf P, Gaudart J, Castelli F, Brouqui P, von Sonnenburg F, Loutan L, Parola P: Multicenter EuroTravNet/GeoSentinel study of travel-related infectious diseases in Europe. Emerg Infect Dis 2009, 15:1783-1790.
3. Warne B, Weld LH, Cramer JP, Field VK, Grobusch MP, Caumes E, Jensenius M, Gautret P, Schlagenhauf P, Castelli F, Lalloo DG, Ursing J, Chappuis F, von Sonnenburg F, López-Vélez R, Rapp C, Smith KC, Parola P, Gkrania-Klotsas E, EuroTravNet Network: Travel-related infection in European travelers, EuroTravNet 2011. J Travel Med 2014, 21:248-254.
4. Visser BJ, van Vugt M, Grobusch MP: Malaria: an update on current chemotherapy. Exp Opin Pharmacother 2014, 15(15):2219-2254.
5. van Vugt M, van Beest A, Sicuri E, van Tulder M, Grobusch MP: Malaria treatment and prophylaxis in endemic and nonendemic countries: evidence on strategies and their cost-effectiveness. Future Microbiol 2011, 6:1485-1500.
6. Obare P, Ogutu B, Adams M, Odera JS, Lilley K, Dosoo D, Adhiambo C, Owusu-Agyei S, Binka F, Wanja E, Johnson J: Misclassification of Plasmodium infections by conventional microscopy and the impact of remedial training on the proficiency of laboratory technicians in species identification. Malar J 2013, 12:113.
7. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM: Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J 2013, 12:8.
8. Mombo-Ngoma G, Kleine C, Basra A, Wurbel H, Diop DA, Capan M, Adegnika AA, Kurth F, Mordmuller B, Joanny F, Kremsner PG, Ramharter M, Bélard S: Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. Malar J 2012, 11:120.
9. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ: Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010, 10:673-681.
10. Kilian AH, Metzger WG, Mutschelknauss EJ, Kabagambe G, Langi P, Korte R, von Sonnenburg F: Reliability of malaria microscopy in epidemiological studies: results of quality control. Trop Med Int Health 2000, 5:3-8.
11. McKenzie FE, Sirichaisinthop J, Miller RS, Gasser RA Jr, Wongsrichanalai C: Dependence of malaria detection and species diagnosis by microscopy on parasite density. Am J Trop Med Hyg 2003, 69:372-376.
12. Grobusch MP, Hanscheid T, Zoller T, Jelinek T, Burchard GD: Rapid immunochromatographic malarial antigen detection unreliable for detecting Plasmodium malariae and Plasmodium ovale. Eur J Clin Microbiol Infect Dis 2002, 21:818-820.
13. Foster D, Cox-Singh J, Mohamad DS, Krishna S, Chin PP, Singh B: Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi. Malar J 2014, 13:60.
14. Baird JK: Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004, 48:4075-4083.
15. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ: Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 2014, 14:982-991.
16. World Health Organization: Guidelines for the Treatment of Malaria. 2nd edition. Geneva, Switzerland: WHO Press, World Health Organization; 2010.
17. Maguire JD, Sumawinata IW, Masbar S, Laksana B, Prodjodipuro P, Susanti I, Sismadi P, Mahmud N, Bangs MJ, Baird JK: Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002, 360:58-60.
18. Mars U, Larsson BS: Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res 1999, 12:266-274.
19. Taylor WR, White NJ: Antimalarial drug toxicity: a review. Drug Saf 2004, 27:25-61.
20. Naing C, Whittaker MA, Nyunt Wai V, Mak JW: Is Plasmodium vivax malaria a severe malaria?: a systematic review and meta-analysis. PLoS Negl Trop Dis 2014, 8:e3071.
21. Bouchaud O, Muhlberger N, Parola P, Calleri G, Matteelli A, Peyerl-Hoffmann G, Mechai F, Gautret P, Clerinx J, Kremsner PG, Jelinek T, Kaiser A, Beltrame A, Schmid ML, Kern P, Probst M, Bartoloni A, Weinke T, Grobusch MP: Therapy of uncomplicated falciparum malaria in Europe: MALTHER-a prospective observational multicentre study. Malar J 2012, 11:8.
22. WHO: Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. ISBN 9789241597531.
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
24. Efficacy and Safety of Artemisinin Combination Therapy (ACT) for Non-falciparum Malaria in Travellers: A Systematic Review. [http://www.crd.york.ac. uk/PROSPERO/display-record.asp?ID=CRD42014009103]
25. PiDan L, Yi L, ChangJi M: Observation on the effect of artesunate and artemether on patients with G6PD deficiency vivax malaria patients. China Trop Med 2009, 9:457-458.
26. Yoda T, Rakue Y, Mizota T, Looaresowan S: Clinical trial of efficacy of artesunate against Plasmodium vivax malaria in a Bangkok Hospital. J Tokyo Med Univ 2005, 63:480-484.
27. Muhlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjorup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJ, Kern P, Fry G, et al: Epidemiology and clinical features of vivax malaria imported to Europe: Sentinel surveillance data from TropNetEurop. Malar J 2004, 3:1-7.
28. Hwang J, Alemayehu BH, Reithinger R, Tekleyohannes SG, Takele T, Birhanu SG, Demeke L, Hoos D, Melaku Z, Kassa M, Jima D, Malone JL, Nettey H, Green M, Poe A, Akinyi S, Udhayakumar V, Kachur SP, Filler S: In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia. PLoS One 2013, 8:e63433.
29. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P: Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg 2011, 84:137-140.
30. Li X, Li C, Che L, Liu X, Li Z, Huang D, He W, Dao Q: [Observation on efficacy of artemether compound against vivax malaria] (in Chinese). Chung-Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih Chinese J Parasitol Parasitic Dis 1999, 17:175-177.
31. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, Wilairatana P, Kano S, Ringwald P, Looareesuwan S: Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 2007, 45:111-114.
32. Eibach D, Ceron N, Krishnalall K, Carter K, Bonnot G, Bienvenu AL, Picot S: Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. Malar J 2012, 11:347.
33. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, Ringwald P: Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 2013, 57:818-826.
34. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F: Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011, 53:977-984.
35. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NP, Singhasivanon P, White NJ, Kaker F: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J 2010, 9:105.
36. Kolaczinski K, Durrani N, Rahim S, Rowland M: Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. Trans R Soc Trop Med Hyg 2007, 101:1081-1087.
37. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM: Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002, 46:3947-3953.
38. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM: A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008, 359:2545-2557.
39. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L: Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011, 6:e14501.
40. Liu R, Dong HF, Jiang MS: A pharmacokinetic approach to assess artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria. Expert Rev Clin Pharmacol 2012, 5:521-524.
41. Mohapatra MK, Dash LK, Mohapatra A: Severe vivax malaria: a study on its clinical manifestations, risk factors, outcome and therapeutic efficacy of artesunate. Int J Clin Case Reports 2013, 3:doi:10.5376.
42. Dao NV, Cuong BT, Ngoa ND, Duy DN, Dai B, Thanh NX, Chavchich M, Rieckmann KH, Edstein MD: Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. Trans R Soc Trop Med Hyg 2007, 101:534-539.
43. Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D: Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. [Update of Cochrane Database Syst Rev 2011, 7:CD008492; PMID: 21735431] Cochrane Database of Systematic Rev 2013, 10:CD008492.
44. Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, Li CF: Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province. China Malar J 2013, 12:409.
45. Senn N, Rarau P, Manong D, Salib M, Siba P, Reeder JC, Rogerson SJ, Genton B, Mueller I: Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea. Clin Infect Dis 2013, 56:1413-1420.
46. Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, Anstey NM, Yeo TW: A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013, 56:383-397.
47. Abdallah TM, Ali AA, Bakri M, Gasim GI, Musa IR, Adam I: Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan. Malar J 2012, 11:404.
48. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S: Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 2004, 35:570-574.
49. Karunajeewa HA, Kemiki A, Alpers MP, Lorry K, Batty KT, Ilett KF, Davis TM: Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatr Infect Dis J 2003, 22:251-256.
50. Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, Gosi P, Lanteri C, Chaorattanakawee S, Sriwichai S, Chann S, Kuntawunginn W, Buathong N, Nou S, Walsh DS, Tyner SD, Juliano JJ, Lin J, Spring M, Bethell D, Kaewkungwal J, Tang D, Chuor CM, Satharath P, Saunders D: Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in Northern Cambodia: An open-label randomized trial. PLoS One 2014, 9:e93138.
51. Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, Pasaribu S, Imwong M, White NJ, Dondorp AM: A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatra, Indonesia. J Infect Dis 2013, 208:1906-1913.
52. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK: Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 2013, 57:1128-1135.
53. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S: High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2008, 78:736-740.
54. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN: Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007, 44:1067-1074.
55. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN: Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
56. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM, Looareesuwan S: Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 2003, 69:14-18.
57. da Silva RS, Pinto AY, Calvosa VS, De Souza JM: [Short course schemes for vivax malaria treatment](in Portuguese). Rev Soc Bras Med Trop 2003, 36:235-239.
58. Phan GT, de Vries PJ, Tran BQ, Le HQ, Nguyen NV, Nguyen TV, Heisterkamp SH, Kager PA: Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int Health 2002, 7:858-864.
59. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ: Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000, 44:1680-1685.
60. Wilairatana P, Silachamroon U, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, Phumratanaprapin W, Srivilirit S, Looareesuwan S: Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 1999, 61:973-977.
61. Same-Ekobo A, Lohoue J, Essono E, Ravinet L, Ducret J-P: [Résolution rapide des acces palustres a Plasmodium ovale par l'artesunate (Arsumax®)](in French). Méd Trop (Mars) 1999, 59:43-45.
62. Borrmann S, Szlezak N, Binder RK, Missinou MA, Lell B, Kremsner PG: Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections. J Antimicrob Chemother 2002, 50:751-754.
63. Tjitra E, Hasugian AR, Siswantoro H, Prasetyorini B, Ekowatiningsih R, Yusnita EA, Purnamasari T, Driyah S, Salwati E, Nurhayati Yuwarni E, Januar L, Labora J, Wijayanto B, Amansyah F, Dedang TA, Purnama A: Trihono: Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J 2012, 11:153.
64. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F: A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 2005, 41:425-432.
65. Barber BE, William T, Jikal M, Jilip J, Dhararaj P, Menon J, Yeo TW, Anstey NM: Plasmodium knowlesi malaria in children. Emerg Infect Dis 2011, 17:814-820.
66. William T, Menon J, Rajahram G, Chan L, Ma G, Donaldson S, Khoo S, Frederick C, Jelip J, Anstey NM, Yeo TW: Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011, 17:1248-1255.
67. Alam MT, Bora H, Bharti PK, Saifi MA, Das MK, Dev V, Kumar A, Singh N, Dash AP, Das B, Wajihullah Sharma YD: Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. Antimicrob Agents Chemother 2007, 51:857-863.
68. Awab GR, Pukrittayakamee S, Jamornthanyawat N, Yamin F, Dondorp AM, Day NPJ, White NJ, Woodrow CJ, Imwong M: Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. Malar J 2013, 12:19.
69. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, Se Y, Somethy S, Phann ST, Chann S, Sriwichai S, Buathong N, Kuntawunginn W, Mitprasat M, Siripokasupkul R, Teja-Isavadharm P, Soh E, Timmermans A, Lanteri C, Kaewkungwal J, Auayporn M, Tang D, Chour CM, Prom S, Haigney M, Cantilena L, Saunders D: Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother 2014, 58(10):6056-6067.
70. Maguire JD, Baird JK: The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies. Ann Trop Med Parasitol 2010, 104:283-301.
71. Nakajima Y, Suganuma K, Sakamoto M, Osone Y, Akizuki S: [A case of non-Japanese patient with severe co-infection with Plasmodium falciparum and Plasmodium malariae successfully treated with intravenous artesunate](in Japanese). Japanese J Chemother 2009, 57:311-315.
72. Calleri G, Balbiano R, Caramello P: Are artemisinin-based combination therapies effective against Plasmodium malariae? J Antimicrob Chemother 2013, 68:1447-1448.
73. Singh B, Daneshvar C: Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013, 26:165-184.
74. WHO: Management of Severe Malaria-A Practical Handbook. Thirdth edition. Geneva: World Health Organization; 2013.
75. Lau YL, Tan LH, Chin LC, Fong MY, Noraishah MA, Rohela M: Plasmodium knowlesi reinfection in human. Emerg Infect Dis 2011, 17:1314-1315.
76. Orth H, Jensen BO, Holtfreter MC, Kocheril SJ, Mallach S, MacKenzie C, Muller-Stover I, Henrich B, Imwong M, White NJ, Häussinger D, Richter J: Plasmodium knowlesi infection imported to Germany. Euro Surveill 2013, 18.
77. WHO: World Malaria Report 2013. Geneva: World Health Organization; 2013 [http://www.who.int/malaria/publications/world-malaria-report-2013/report/en/]
78. Kusriastuti R, Surya A: New treatment policy of malaria as a part of malaria control program in Indonesia. Acta Med Indones 2012, 44:265-269.
79. Rieckmann KH, Davis DR, Hutton DC: Plasmodium vivax resistance to chloroquine? Lancet 1989, 2:1183-1184.
80. Baird JK, Leksana B, Masbar S, Suradi Sutanihardja MA, Fryauff DJ, Subianto B: Whole blood chloroquine concentrations with Plasmodium vivax infection in Irian Jaya, Indonesia. Am J Trop Med Hyg 1997, 56:618-620.
81. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL: Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995, 171:1678-1682.
82. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN: Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 2007, 101:351-359.
83. Sumawinata IW, Bernadeta Leksana B, Sutamihardja A, Purnomo Subianto B, Sekartuti Fryauff DJ, Baird JK: Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003, 68:416-420.
84. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin M, Zaw T, Annerberg A, de Radigues X, Nosten F: Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health 2008, 13:91-98.
85. Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP: Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J 2005, 48:141-150.
86. Taylor WR, Doan HN, Nguyen DT, Tran TU, Fryauff DJ, Gomez-Saladin E, Kain KC, Le DC, Baird JK: Assessing drug sensitivity of Plasmodium vivax to halofantrine or choroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction genotyping. Am J Trop Med Hyg 2000, 62:693-697.
87. Kurcer MA, Simsek Z, Kurcer Z: The decreasing efficacy of chloroquine in the treatment of Plasmodium vivax malaria, in Sanliurfa, south-eastern Turkey. Ann Trop Med Parasitol 2006, 100:109-113.
88. Kurcer MA, Simsek Z, Zeyrek FY, Atay S, Celik H, Kat I, Topluoglu S: Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol 2004, 98:447-451.
89. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, Dunne M, Berman J: Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg 2001, 65:90-93.
90. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, Barbosa M, Alecrim WD, Alecrim M: Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 2007, 13:1125-1126.
91. Marques MM, Costa MR, Santana Filho FS, Vieira JL, Nascimento MT, Brasil LW, Nogueira F, Silveira H, Reyes-Lecca RC, Monteiro WM, Lacerda MV, Alecrim MG: Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrob Agents Chemother 2014, 58:342-347.
92. Ketema T, Bacha K, Birhanu T, Petros B: Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J 2009, 8:177.
93. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G, Aseffa A, Engers H: Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit. Ethiopia Malar J 2008, 7:220.
94. Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, Medhin G, Velavan TP: Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J 2014, 13:244.
95. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RGA: The changing epidemiology of malaria elimination: New strategies for new challenges. Lancet 2013, 382:900-911.
96. White NJ: Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999, 41:301-308.
97. Askling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, Lopez-Velez R, Paul M, Petersen E, Popescu C, Ramharter M, Schlagenhauf P: European Society for Clinical Microbiology and Infectious Diseases Study Group on Clinical Parasitology: Management of imported malaria in Europe. Malar J 2012, 11:328.
98. Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG: Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J 2008, 7(Suppl 1):S7.
99. Tabernero P, Fernandez FM, Green M, Guerin PJ, Newton PN: Mind the gaps-the epidemiology of poor-quality anti-malarials in the malarious world-analysis of the WorldWide Antimalarial Resistance Network database. Malar J 2014, 13:139.
100. Amaratunga C, Sreng S, Mao S, Tullo GS, Anderson JM, Chuor CM, Suon S, Fairhurst RM: Chloroquine remains effective for treating Plasmodium vivax malaria in Pursat province, Western Cambodia. Antimicrob Agents Chemother 2014, 58:6270-6272.
101. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ: Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinffi-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008, 52:1052-1061.
102. Krishna S, White NJ: Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996, 30:263-299.
103. Li Q, O'Neil M, Xie L, Caridha D, Zeng Q, Zhang J, Pybus B, Hickman M, Melendez V: Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malar J 2014, 13:141.
104. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L: Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014, 383:1049-1058.
105. PubMed United States National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894. Accessed on December 3 2014. 2001-2014. Available at: www.pubmed.gov.
106. Dinko B, Oguike MC, Larbi JA, Bousema T, Sutherland CJ: Persistent detection of Plasmodium falciparum, P. malariae, P. ovale curtisi and P. ovale wallikeri after ACT treatment of asymptomatic Ghanaian schoolchildren. Int J Parasitol Drugs Drug Resist 2013, 3:45-50.
107. Four Artemisinin-Based Combinations (4ABC) Study Group: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011, 8:e1001119.
108. Barnadas C, Ratsimbasoa A, Ranaivosoa H, Ralaizandry D, Raveloariseheno D, Rabekotonorina V, Picot S, Menard D: Prevalence and chloroquine sensitivity of Plasmodium malariae in Madagascar. Am J Trop Med Hyg 2007, 77:1039-1042.
109. Siswantoro H, Russell B, Ratcliff A, Prasetyorini B, Chalfein F, Marfurt J, Kenangalem E, Wuwung M, Piera KA, Ebsworth EP, Anstey NM, Tjitra E, Price RN: In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother 2011, 55:197-202.
110. Barber BE: A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2014, 58:608.
111. Muller M, Schlagenhauf P: Plasmodium knowlesi in travellers, update 2013. Int J Infect Dis 2014, 22:55-64.
112. Rajahram GS, Barber BE, Yeo TW, Tan WW, William T: Case report: Fatal Plasmodium knowlesi malaria following an atypical clinical presentation and delayed diagnosis. Med J Malaysia 2013, 68:71-72.
113. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B: Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008, 46:165-171.
114. Kantele A, Jokiranta TS: Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis 2011, 52:1356-1362.
115. Rajahram GS, Barber BE, William T, Menon J, Anstey NM, Yeo TW: Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J 2012, 11:284.
116. Grigg MJ, William T, Dhanaraj P, Menon J, Barber BE, von Seidlein L, Rajahram G, Price RN, Anstey NM, Yeo TW: A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial). BMJ Open 2014, 4:e006005.
117. Visser BJ, Buijink AW, Grobusch MP: Reporting of medical research costs. Improving transparency and reproducibility of medical research. Methods Inf Med 2014, 53:329-331.